吉西他滨联合替吉奥治疗晚期胰腺癌的疗效和安全性  

Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer

作　　者：江英强 钟惠[1] 何平[1] 郑连喜[1] 杨科[1] 

机构地区：[1]攀钢集团总医院肿瘤科,攀枝花617023

出　　处：《中华肿瘤杂志》2015年第6期472-475,共4页Chinese Journal of Oncology

摘　　要：目的：探讨吉西他滨联合替吉奥治疗晚期胰腺癌的疗效和安全性。方法回顾性分析49例未接受放化疗的晚期胰腺癌患者的临床资料，其中研究组25例，对照组24例。研究组患者给予吉西他滨1000 mg／m2，第1、8天静脉滴注；同时给予替吉奥80 mg／m2，第1～14天分早晚2次口服，21 d为1个化疗周期。对照组给予GEMOX方案，即吉西他滨1000 mg／m2，第1、8天静脉滴注；奥沙利铂130 mg／m2，第1天静脉滴注，21 d为1个化疗周期。观察研究组和对照组患者的疗效和毒副反应。结果研究组患者的有效率为32．0％，疾病控制率为72．0％；对照组患者的有效率为25．0％，疾病控制率为58．3％，差异均无统计学意义（均P＞0．05）。研究组和对照组患者的临床受益率分别为80．0％和50．0％，差异有统计学意义（P＜0．05）。研究组和对照组患者的中位生存时间分别为9．7和9．0个月，差异有统计学意义（ P＜0．05）。两组患者的药物毒副反应均能耐受，无化疗相关性死亡患者。毒副反应主要表现为骨髓抑制和消化道反应，且研究组患者的治疗毒副反应发生率低于对照组。结论吉西他滨联合替吉奥治疗晚期胰腺癌安全、有效，且毒副反应较轻，患者可以耐受。Objective To evaluate the safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer. Methods A retrospective analysis of the clinical data of 49 patients with advanced pancreatic cancer, who did not receive radiotherapy and chemotherapy, were divided into two groups：the study group （25 cases）, and control group （24 cases）. Patients in the study group received gemcitabine 1 000 mg/m2 via intravenous drip at the first and 8th days, and received S-1 80 mg/m2, morning and evening （twice a day） for the first 14 days, and 21 days as a treatment cycle of chemotherapy.The control group was given GEMOX regimen：Gemcitabine 1 000 mg/m2 via intravenous drip at the first and 8 days, and oxaliplatin 130 mg/m2 via intravenous drip at the first day, and 21 d for a treatment cycle of chemotherapy. The efficacy and adverse reactions in patients of the study and control groups were observed and compared. Results The efficiency of the study group was 32. 0% and disease control rate was 72.0%. The efficiency of the control group was 25.0% and disease control rate was 58.3%. The differences between the two groups were statistically not significant （ P〉0. 05 for all ） . The clinical benefit rate in the study group and control group were 80.0% and 50.0%, respectively, showing a significant difference （ P〈0.05） . The median survival time was 9.7 months in patients of the study group and 9.0 months in the control group, with a significant difference （P〈0.05）. The drug toxicity was well tolerated in both groups, and no chemotherapy-related death occurred. The major adverse reactions were myelosuppression and digestive tract reactions, and the adverse reactions in the study group were lower than those in the control group. Conclusions Gemcitabine combined with S-1 is effective and safe in the treatment of advanced pancreatic cancer, with less side effects, and can be tolerated by the patients.

关 键 词：胰腺肿瘤 药物疗法 吉西他滨 奥沙利铂 替吉奥 安全 

分 类 号：R735.9[医药卫生—肿瘤]